|
To listen to individual tracks now, click the  icon. To download tracks to a CD, right-click the icon for your preferred file type. Files are provided in WMA for users with Windows Media Player or  MP3 for users with other audio players.
|
| Track 1 |
Introduction by Neil Love, MD |
|
|
| Track 2 |
Clinical implications of 68-month data from the ATAC trial |
|
|
| Track 3 |
Potential role of aromatase inhibitors in the prevention setting |
|
|
| Track 4 |
Initial results of the BIG 1-98 trial |
|
|
| Track 5 |
Lack of differential effect of letrozole in ER/PR phenotypes in BIG 1-98 |
|
|
| Track 6 |
Increased hysterectomy rates with tamoxifen versus anastrozole in ATAC |
|
|
| Track 7 |
Use of vitamin D for arthralgiaswith aromatase inhibitors |
|
|
| Track 8 |
Reduction in fracture rate with anastrozole in ATAC at 68 months |
|
|
| Track 9 |
Bone mineral density changes with aromatase inhibitors |
|
|
| Track 10 |
Cardiac events with aromatase inhibitors versus tamoxifen |
|
|
| Track 11 |
Evaluation of serum lipid profiles in clinical trials of adjuvant aromatase inhibitors |
|
|
| Track 12 |
Cardiac effects of tamoxifen |
|
|
| Track 13 |
Differential rates of cardiac events with various aromatase inhibitors |
|
|
| Track 14 |
Endocrine therapy after five years of anastrozole |
|
|
| Track 15 |
Selection of aromatase inhibitors at different time points in adjuvant treatment |
|
|
| Track 16 |
Nonprotocol use of LHRH agonists with aromatase inhibitors in premenopausal patients |
|
|
| |
|
|
|
 |
William J Gradishar, MD
Director, Breast Medical Oncology
Associate Professor of Medicine
Robert H Lurie Comprehensive Cancer Center
Northwestern University
Feinberg School of Medicine
Chicago, Illinois
Click here to download the entire interview |
|
|
|
| Track 1 |
Introduction by Dr Love |
|
|
| Track 2 |
Efficacy and tolerability of capecitabine/paclitaxel |
|
|
| Track 3 |
Earlier use of capecitabine in the metastatic setting |
|
|
| Track 4 |
Mechanism of action of nanoparticle albumin-bound (nab) paclitaxel (Abraxane®) |
|
|
| Track 5 |
Phase III pivotal trial: Nab paclitaxel versus paclitaxel for metastatic disease |
|
|
| Track 6 |
Weekly nab paclitaxel in patients with taxane-refractory metastatic breast cancer |
|
|
| Track 7 |
Selection of adjuvant hormonal therapy at different time points in treatment |
|
|
| Track 8 |
CALGB-49907: AC or CMF versus capecitabine in elderly patients |
|
|
| Track 9 |
Evaluation of the benefit of adjuvant chemotherapy in the elderly |
|
|
| Track 10 |
The Evaluation of Fulvestrant versus Exemestane Clinical Trial (EFECT) |
|
|
| Track 11 |
Dose and schedule of fulvestrant |
|
|
| Track 12 |
Ongoing trials of fulvestrant in combination with hormonal and biologic agents |
|
|
|
| Track 1 |
Introduction by Dr Love |
|
|
| Track 2 |
ABCSG-12: Goserelin/tamoxifen versus goserelin/anastrozole with or without zoledronic acid |
|
|
| Track 3 |
Comparison of ABCSG-12 with the TEXT and SOFT trials |
|
|
| Track 4 |
Nonprotocol use of LHRH agonists with aromatase inhibitors in premenopausal patients |
|
|
| Track 5 |
Use of bisphosphonates for therapy-induced bone loss |
|
|
| Track 6 |
Clinical management of bone loss in postmenopausal patients |
|
|
| Track 7 |
Importance of outdoor exercise in preventing bone loss |
|
|
| Track 8 |
Austrian-German trial of switching to anastrozole after two years of adjuvant tamoxifen |
|
|
| Track 9 |
Comparability of the Austrian-German and IES trials |
|
|
| |
|
|
|
 |
Edith A Perez, MD
Professor of Medicine, Mayo Medical School
Director, Cancer Clinical Study Unit
Director, Breast Cancer Program
Division of Hematology and Oncology, Mayo Clinic
Jacksonville, Florida
Click here to download the entire interview |
|
|
|
| Track 1 |
Introduction by Dr Love |
|
|
| Track 2 |
Cardiac events in the Intergroup N9831 trial |
|
|
| Track 3 |
Left ventricular ejection fraction changes associated with trastuzumab |
|
|
| Track 4 |
Upcoming combined analysis of Intergroup N9831 and NSABP-B-31 |
|
|
| Track 5 |
Design and background of the BCIRG-006 and HERA adjuvant trastuzumab trials |
|
|
| Track 6 |
Perspectives on the MD Anderson neoadjuvant trastuzumab data |
|
|
| Track 7 |
Proposed neoadjuvant/adjuvant Intergroup trial for patients with HER2-positive disease |
|
|
| Track 8 |
Synergy between lapatinib and trastuzumab |
|
|
| Track 9 |
Formulation and dosing of nab paclitaxel |
|
|
| Track 10 |
Phase III pivotal trial: Nab paclitaxel versus paclitaxel for metastatic disease |
|
|
| Track 11 |
Rapid resolution of sensory neuropathy with nab paclitaxel |
|
|
| Track 12 |
Weekly administration of nab paclitaxel |
|
|
| Track 13 |
Incorporation of nab paclitaxel into the treatment algorithm |
|
|
|
|
